HOFLAND et al.

Appl. No. 10/591,847

Atty. Ref.: 620-454 Amendment

February 20, 2009

AMENDMENTS TO THE CLAIMS:

Please amend the claims as follows:

- 1. (Original) A method of treatment of a tumour cell which comprises administering to a subject in need of treatment an effective amount of a topoisomerase-II poison in combination with a bis-dioxypiperazine, wherein said subject is further treated with radiation.
- 2. (Original) A method according to claim 1 wherein the topoisomerase-II poison is etoposide.
- 3. (Previously Presented) A method according to claim 1 wherein the bisdioxypiperazine is dexrazoxane.
- 4. (Previously Presented) A method according to claim 1, wherein the tumour is a CNS tumour.
- 5. (Currently Amended) A topoisomerase-II poison and a bis-dioxypiperazine, as a combined preparation for simultaneous, separate or sequential use in tumour therapy of a patient undergoing radiation treatment wherein either said topoisomerase-II poison is in an orally administerable form and said bis-dioxypiperazine is in an infusible form, or said topoisomerase-II poison is in an infusible form and said bis-dioxypiperazine is in an orally administerable form.
- 6. (Original) A topoisomerase-II poison, a bis-dioxypiperazine and a source of ionising radiation as a combined preparation for simultaneous, separate or sequential of the topoisomerase-II poison and bis-dioxypiperazine and separate or sequential use of the source of ionising radiation in tumour therapy.

- 2 -

1441107

HOFLAND et al. Appl. No. 10/591,847 Atty. Ref.: 620-454

Amendment

February 20, 2009

7. (Original) A topoisomerase-II poison, a bis-dioxypiperazine and ionising radiation as a combined preparation for separate or sequential use in tumour therapy.

- 8. (Original) A combined preparation for use according to claim 7 wherein the topoisomerase-II poison is etoposide.
- 9. (Previously Presented) A combined preparation for use according to claim 7wherein the bis-dioxypiperazine is dexrazoxane.
- 10. (Previously Presented) A combined preparation for use according to claim 7, wherein the tumour is a CNS tumour.